Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Recurrence × lenvatinib × Clear all

Status

Sponsor Class

Study Type

Interventional 7 Observational 1

Sponsor

Conditions

Carcinoma, Hepatocellular 14 Cholangiocarcinoma 3 Thyroid Neoplasms 2 Recurrence 1 Liver Neoplasms 1 Liver Diseases 1 Coitus 1 Carcinoma, Renal Cell 1 Biliary Tract Neoplasms 1

Interventions

Surgical Procedures, Operative 6 Lenalidomide 4 Liver Transplantation 3 Liquid Biopsy 3 Blood Specimen Collection 3 pomalidomide 2 gilteritinib 2 Therapeutics 2 Observation 2 Neoadjuvant Therapy 2 Mitomycin 2 Magnetic Resonance Spectroscopy 2 High-Throughput Nucleotide Sequencing 2 DNA, Mitochondrial 2 Brentuximab Vedotin 2 trametinib 1 romidepsin 1 nedaplatin 1 lenvatinib 1 fluoroazomycin arabinoside 1 exemestane 1 elotuzumab 1 dacomitinib 1 dabrafenib 1 copanlisib 1 Whole Genome Sequencing 1 Transcranial Magnetic Stimulation 1 Toremifene 1 Tegafur 1 Tamoxifen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06253364 2024-03-13

VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy

Tongji Hospital

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡